CD8A and non-small cell lung carcinoma: In addition, it has been reported that the increased T cell receptor (TCR) diversity of peripheral PD-1+CD8+ T cells before treatment in patients with non-small cell lung cancer was associated with better clinical outcome in checkpoint blockade therapy [52].